Brief: AFT Pharmaceuticals Enters Late-Stage R+D Agreement For Novel Injectable
21/10/2024 01:33
Oct 21 (Reuters) - AFT Pharmaceuticals Ltd AFT.NZ :
* ENTERS LATE-STAGE R+D AGREEMENT FOR A NOVEL INJECTABLE
* ENTERED INTO AN AGREEMENT WITH TWO EUROPEAN PARTNERS
* AGREEMENT FOR A NOVEL INJECTABLE MEDICINE CONTAINING A
PATENTED
NEW CHEMICAL ENTITY
Further company coverage: AFT.NZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AFT Pharmaceuticals
See all newsNZ's AFT Pharma eyes highest weekly gain in over 2 months after results
Brief: AFT Pharmaceuticals Reports Double Digit Revenue Growth In 1H FY27
NZ's AFT Pharmaceuticals gains most in over 2 weeks on strong half-year results
Brief: AFT Pharmaceuticals Enters Exclusive Development, License And Supply Agreement With Mikasaseiyaku
NZ's AFT Pharma rises to near 1-month high on Japan licensing deal for Maxigesic IV